Advertisement

Pharmacological and Dietary Control of Platelet Vessel Wall Inter-Actions in Normal and Pathological Conditions

  • E. Tremoli
  • C. Galli
  • R. Paoletti
Conference paper
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 51)

Abstract

A number of recent experimental and clinical studies deals with the role of platelets in the development of atherosclerosis and of thromboembolic diseases (1,2). The interaction between platelets and vessel walls has been the object of extensive studies on the basis of the recent discovery of the modulators of platelet homeostasis, prostacyclin and thromboxane (3,4).

Keywords

Arachidonic Acid Platelet Aggregation Release Reaction Human Blood Platelet Alpha Granule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M. B. Stemerman, Haemostasis, thrombosis and atherogenesis, in “Atherosclerosis Reviews”, vol. 6, M. Gotto and R. Paoletti, eds., Raven Press, New York (1979).Google Scholar
  2. 2.
    T. H. Spaet, Hemostatic homeostasis, Blood, 28: 112 (1966).Google Scholar
  3. 3.
    M. Hamberg, J. Svensson and B. Samuelsson, Thromboxanes a new group of biologically active compounds derived from prostaglandin endoperoxides, Proc. Natl. Acad. Sci. USA, 72:2994 (1975).PubMedCrossRefGoogle Scholar
  4. 4.
    S. Moncada, E. A. Higgs and J. R. Vane, Human arterial and venous tissues generate prostacyclin (prostaglandin X) a potent inhibitor of platelet aggregation, Lancet, 1: 18Google Scholar
  5. 5.
    J. F. Mustard and M. A. Packham, Factors affecting platelet function: adhesion, release and aggregation, Pharmacol. Rev. 22:97 (1970).PubMedGoogle Scholar
  6. 6.
    J. F. Mustard, W. D. Perry, R. L. Kinlough Rathbone, and M. A. Packham, Factors responsible for ADP induced release reaction of human platelets, Am. J. Physiol., 228:1757 (1975).PubMedGoogle Scholar
  7. 7.
    H. J. Weiss, The role of biologically active lipids in platelet aggregation, New Engl. J. Med., 293:531, 580 (1975).PubMedCrossRefGoogle Scholar
  8. 8.
    B. B. Vargaftig, M. Chignard, and J. Lefort, Platelet secretion (release reaction). Mechanisms and pharmacology, in “Prostaglandins Immunopharmacology, Proceedings of the VII Int. Congress on Pharmacology”, B. B. Vargaftig ed., Pergamon Press Publ., New York, p. 97 (1979).Google Scholar
  9. 9.
    H. Holmsen, Prostaglandin-Endoperoxide-Thromboxane synthesis and dense granule secretion as positive feed back loops in the preparation of platelet responses during the “basic release reaction”, in “Prostaglandins Immunopharmacology, Proceedings of the VII Jnt. Congress on Pharmacology”, B. B. Vargaftig ed., Pergamon Press, New York (1979).Google Scholar
  10. 10.
    R. L. Kinlough Rathbone, M. A. Packham, H. J. Reimers, J. P. Cazenave, and J. F. Mustard, Mechanisms of platelet shape change, aggregation and release induced by collagen, thrombin or A23, 187, J. Lab. Clin. Med., 90: 707 (1977).Google Scholar
  11. 11.
    D. M. Tollefsen, J. R. Feagler, and P. W. Majerus, The binding of thrombin to the surface of human platelets, J. Biol. Chem., 249:2646 (1974).Google Scholar
  12. 12.
    M. A. Packham, M. A. Guccione, J. P. Greenberg, R. L. Kinlough-Rathbone, and J. F. Mustard, Release of C serotonin during intra platelet changes induced by thrombin and collagen, Blood, 50: 915 (1977).PubMedGoogle Scholar
  13. 13.
    M. Chignard, J. P. Le Couedic, M. Tence, B. B. Vargaftig, and J. Benveniste, The role of platelet activating factor in platelet aggregation, Nature, 279: 799 (1979).Google Scholar
  14. 14.
    D. C. B. Mills and G. C. K. Roberts, Effects of adrenaline on human blood platelets, J. Physiol., 193:443 (1967).Google Scholar
  15. 15.
    M. G. Davey and E. F. Luscher, Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets, Nature, 216: 857 (1967).PubMedCrossRefGoogle Scholar
  16. 16.
    H. Holmsen, Biochemistry of the platelet release reaction, in “Biochemistry and Pharmacology of Platelets”, Ciba Foundation Symposium, Elsevier North Holland Biomedical Press, Amsterdam, p. 175 (1975).Google Scholar
  17. 17.
    H. Holmsen, The platelet, its membrane physiology and biochemistry, in “Clinics in Hematology”, W. B. Sanders Co., London, 2: 235 (1972).Google Scholar
  18. 18.
    M. E. Bentfield and D. F. Bainton, Cytochemical localization of lysosomal enzymes in rat megakaryocytes and platelets, J. Clin. Invest., 56:1635 (1975).Google Scholar
  19. 19.
    R. V. Buker, H. Blaschko and G. V. R. Born, The isolation from blood platelets of particles containing 5 hydroxy tryptamine and adenosine diphosphate, J. Physiol., 149:55 (1959).Google Scholar
  20. 20.
    R. B. Davis and G. C. White, Localization of 5-hydroxytryptamine in blood platelets, Brit. J. Haematol., 15:93 (1968).Google Scholar
  21. 21.
    M. J. Broekman, R. I. Handin and P. Cohen, Distribution of fibrinogen and platelet factor 4 an XIII in subcellular fractions of human platelets, Brit. J. Haematol., 31:51 (1975).Google Scholar
  22. 22.
    K. I. Kaplan, J. Kaplan, J. Broekman, A. Chernoff, G. R. Lezzink, and H. Drillings, Platelet pha granule proteins: studies on release and subcellular localization, Blood, 53: 604 (1979).PubMedGoogle Scholar
  23. 23.
    B. Rucinski, S. Newiarowski, P. James, D. A. Walz, and A. Z. Budzinski, Antiheparin proteins secreted by human platelets. Purification, characterization and radioimmunoassay, Blood, 53: 47 (1979).PubMedGoogle Scholar
  24. 24.
    J. F. Mustard, Z. Movat, D. R. L. Mac Morine and A. Senyi, Release of permeability factors from blood platelets, Proc. Soc. Exptl. Biol. Med., 119:988 (1965).Google Scholar
  25. 25.
    R. Ross, J. Glomset, B. Kariya and L. Harker, A platelet dependent serum factor that stimulates the proliferation of arterial smooth muscle in vitro, Proc. Natl. Acad. Sci. USA, 71:1207 (1974).Google Scholar
  26. 26.
    A. Siegel and E. F. Luscher, Non identity of the granules of human blood platelets with typical lysosomes, Nature, 215: 745 (1967).PubMedCrossRefGoogle Scholar
  27. 27.
    M. B. Donati and G. de Gaetano, Interaction of fibrin with blood platelets and other cells, in “Comparison of Life Sciences”, vol. 2, B. A. Warner, ed., Van Nostrand Reinhold Co, New York, N.Y., USA, (1981).Google Scholar
  28. 28.
    P. N. Walsh, The effects of collagen and kaolin on the intrinsic coagulant activities of platelets, Brit. J. Haematol., 22:393 (1972).Google Scholar
  29. 29.
    T. H. Spaet and J. Cintron, Studies on platelet factors bio-availability, Brit. J. Haematol., 11:269 (1965).Google Scholar
  30. 30.
    P. N. Walsh, R. E. Goldberg, R. L. Tax, and L. E. Margadal, Platelet coagulant activities and retinal vein thrombosis, Thromb. and Haemost., 38: 399 (1977).Google Scholar
  31. 31.
    N. Semeraro and J. Vermylen, Evidence that washed human platelets possess factor x activator activity, Brit. J. Haematol., 11:269 (1965).Google Scholar
  32. 32.
    E. Tremoli, M. B. Donati and G. de Gaetano, Washed guinea pig and rat platelets possess factor x activating activity, Brit. J. Haematol., 9:155 (1977).Google Scholar
  33. 33.
    E. Tremoli, M. Colucci, M. B. Donati and N. Semeraro, Early increase of a new platelet coagulant activity in rats fed a thrombogenic diet, Atherosclerosis, 33: 239 (1979).PubMedCrossRefGoogle Scholar
  34. 34.
    J. Kloeze, Influence of prostaglandins on platelet adhesive¬ness and platelet aggregation, in “Prostaglandins, Proceedings of the 2nd Noble Symposium”, S. Bergstrom and B. Samuelsson eds., Sune, New York, Interscience (1966).Google Scholar
  35. 35.
    S. Bergstrom, H. Danielsson, and B. Samuelsson, The enzymatic formation of prostaglandin E from arachidonic acid, Biochim. Biophys. Acta, 90:207 (1964).Google Scholar
  36. 36.
    R. J. Gryglewski, J. A. Salmon, F. B. Ubatuba, B. C. Weatherly, S. Moncada, and J. R. Vane, Effects of all cis-5,8,11,14, 17-eicosapentaenoic acid and PGH on platelet aggregation, Prostaglandins, 18: 453 ( 1979.PubMedCrossRefGoogle Scholar
  37. 37.
    J. B. Smith and A. L. Willis, Formation and release of prostaglandins in response to thrombin, Br. J. Pharmacol., 40:545 (1970).Google Scholar
  38. 38.
    H. Shio and P. W. Ramwell, Effect of prostaglandin E and aspirin on the secondary aggregation of human platelets, Nature, 236: 45 (1972).CrossRefGoogle Scholar
  39. 39.
    M. J. Silver, J. B. Smith, C. Ingerman, and J. J. Kosics, Arachidonic acid induced human platelet aggregation and prostaglandin formation, Prostaglandins, 4: 863 (1973).PubMedCrossRefGoogle Scholar
  40. 40.
    M. Hamberg and B. Samuelsson, Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis, Proc. Natl. Acad. Sci. USA, 70:899 (1973).Google Scholar
  41. 41.
    M. Hamberg, J. Svensson, and B. Samuelsson, Thromboxanes a new group of biologically active compounds derived from prostaglandin endoperoxides, Proc. Natl. Acad. Sci. USA, 72:2994 (1975).Google Scholar
  42. 42.
    G. Bereziat, Are phospholipases involved in platelet activation?, Agents and Action, 9: 390 (1979).CrossRefGoogle Scholar
  43. 43.
    S. Hammarstrom, Selective inhibition of platelet n-8 lipooxy-genase by 5,8,11-eicosatryenoic acid, Biochim. Biophys. Acta, 487:517 (1977).Google Scholar
  44. 44.
    B. Samuelsson, P. Borgeat, S. Hammarstrom, and R. C. Murphy, Leukotrienes: a new group of biologically active compounds, in “Adv. in Prostaglandin and Thromboxane Research”, vol. 6, B. Samuelsson, P. W. Ramwell, R. Paoletti, eds., Raven Press, New York, N.Y., p. 1 (1980).Google Scholar
  45. 45.
    A. W. Ford-Hutchinson, M. A. Bray, H. Y. Doig, M. E. Shepley, and M. J. H. Smith, Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes, Nature, 286: 264 (1980).PubMedCrossRefGoogle Scholar
  46. 46.
    H. J. Weiss, L. M. Aledort, and A. S. Koch, The effect of salicylates on the hemostatic properties of platelets in man, J. Clin. Invest., 47:2169 (1968).Google Scholar
  47. 47.
    J. B. Smith, M. J. Silver, C. M. Ingerman, and J. J. Kosics, Prostaglandin D inhibits the aggregation of human platelets, Thromb. Res., 5:291 (1974).Google Scholar
  48. 48.
    J. B. Smith, A. W. Sedar, C. M. Ingerman, and M. J. Silver, Prostaglandin endoperoxides: Platelet shape change, aggregation and the release reaction, in “Platelets and Thrombosis”, D. C. B. Mills and F. I. Pareti eds., p. 83, Academic Press, New York, N.Y. (1977).Google Scholar
  49. 49.
    J. Svensson, M. Hamberg, and B. Samuelsson, On the formation and effects of thromboxane A2 on human platelets, Acta Physiol. Scand., 98:285 (1976).Google Scholar
  50. 50.
    S. Moncada, R. J. Gryglewski, S. Bunting, and J. R. Vane, An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet, Nature, 263: 663 (1976).PubMedCrossRefGoogle Scholar
  51. 51.
    S. Moncada, A. G. Herman, E. A. Higgs, and J. R. Vane, Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the antithrombotic properties of vascular endothelium, NThromb. Res., 3:323 (1977).Google Scholar
  52. 52.
    S. Moncada, J. R. Vane, and B. J. R. Whittle, Relative potency of Prostacyclin, Prostaglandin E1 and D2 as inhibitors of platelet aggregation in several species, J. Physiol., 273:2P (1977).Google Scholar
  53. 53.
    R. J. Gryglewski, R. Korbut, and A. Ocetkiewicz, Reversal of platelet aggregation by prostacyclin, Pharm. Res. Comm., 10:185 (1978).Google Scholar
  54. 54.
    N. G, Ardlie, G. Glew, B. G. Schultz, and C. J. Schwartz, Inhibition and reversal of platelet aggregation by methylxanthines, Thromb. Diath. Haemorrh., 18:670 (1967).Google Scholar
  55. 55.
    R. J. Haslam, Interaction of the pharmacological receptors of blood platelets with adenylate cyclase, Ser. Haematol., 6: 333 (1973).PubMedGoogle Scholar
  56. 56.
    E. W. Salzman, Cyclic AMP and platelet function, N. Engl. J. Med., 286:358 (1972).PubMedCrossRefGoogle Scholar
  57. 57.
    E. W. Salzman, Prostaglandins, Cyclic AMP and platelet function, Thromb. Diath. Haemorrh., 60 (suppl.):311 (1974).Google Scholar
  58. 58.
    E. W. Salzman, J. Lindon, D. Brier, and E. W. Merrill, Surface-induced platelet adhesion, aggregation and release, Ann. N.Y. Acad. Sci. 283:114 (1977).Google Scholar
  59. 59.
    D. C. B. Mills and J. B. Smith, The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′5′-cyclic monophosphate in platelets, Biochem. J., 121: 185 (1971).Google Scholar
  60. 60.
    N. D. Goldberg, R. F. O’Dea, and M.K. Haddox, Cyclic GMP, Adv. Cyclic Nucleotide Res., 3: 155 (1973).Google Scholar
  61. 61.
    L. C. Best, T. J. Martin, R. G. G. Russell, and F. E. Preston, Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets, Nature, 267: 850 (1977).Google Scholar
  62. 62.
    D. C. B. Mills and D. E. MacFarlane, Stimulation of human platelet adenylate cyclase by prostaglandin D2, Thromb. Res., 5:401 (1974).Google Scholar
  63. 63.
    R. R. Gorman, S. Bunting, and O. V. Muller, Modulation of human platelet adenylate cyclase by prostacyclin (Pgx), Prostaglandins, 13: 377 (1977).PubMedGoogle Scholar
  64. 64.
    G. C. LeBreton, D. L. Venton, S. E. Enke, and P. V. Halushka, 13-Azaprostanoic acid: a specific antagonist of human blood platelet thromboxane/endoperoxide receptor, Proc. Natl. Acad. Sci. USA, 76:4097 (1979).Google Scholar
  65. 65.
    D. L. Venton, S. E. Enke, and G. C. Le Breton, Azaprostanoic derivatives. Inhibitors of arachidonic and induced platelet aggregation, J. Med. Chem., 22:824 (1979).Google Scholar
  66. 66.
    A. M. Siegl, J. B. Smith, M. J. Silver, K. C. Nicolaou, G. Gasic, and W. E. Burnette, Binding of prostacyclin by platelets, Federation Proceedings, 37: 260 (1978).Google Scholar
  67. 67.
    G. Di Minno, M. J. Silver, and G. de Gaetano, Prostaglandins as inhibitors of human platelet aggregation, Brit. J. Hematol., 43:637 (1979).Google Scholar
  68. 68.
    J. Mehta and P. Mehta, Enhanced platelet prostaglandin generation and abnormal platelet sensitivity to prostacyclin and thromboxane A in angina pectoris, Blood, 54 (suppl.): 2510 (1979).Google Scholar
  69. 69.
    J. F. Mustard and M. A. Packham, The role of blood platelets in atherosclerosis and the complications of atherosclerosis, Thromb. Diath. Haemorrh., 33:444 (1975).Google Scholar
  70. 70.
    J. A. Colwell, P. V. Halushka, K. E. Sarji, and J. Sagel, Platelet function and diabetes mellitus, Med. Clin. North Am., 62:753 (1978).Google Scholar
  71. 71.
    P. V. Halushka, D. Lurie, and J. A. Colwell, Increased synthesis of prostaglandin E-like material by platelets from patients with diabetes mellitus, N. Engl. J. Med., 297:1306 (1977).Google Scholar
  72. 72.
    M. Lagarde and M. Dechavanne, Increase of platelet prostaglandin cyclic endoperoxides in thrombosis, Lancet, 1: 88 (1977).Google Scholar
  73. 73.
    M. Lagarde and M. Dechavanne, Collagen stimulates more platelet prostaglandin endoperoxides in thrombosis, Biomedicine, 27: 119 (1977).PubMedGoogle Scholar
  74. 74.
    WHO Memorandum, Classification of hyperlipidemias and hyperlipoproteinemias, Circulation, 45: 501 (1975).Google Scholar
  75. 75.
    D. S. Fredrickson, R. I. Levis, and R. S. Lees, Fat trasnport in lipoproteins. An integrated approach to mechanisms and disorders, N. Engl. J. Med., 276:32,94,148,215,273 (1967).Google Scholar
  76. 76.
    K. Westlund and R. Nicolaysen, Serum cholesterol and risk of mortality and morbidity, Scand. J. Clin. Lab. Invest., 87 (suppl.) (1966).Google Scholar
  77. 77.
    A. Nordøy and J. M. Rodset, Platelet function and platelet phospholipids in patients with hyperlipoproteinemia, Acta Med. Scand., 189.:385 (1971).Google Scholar
  78. 78.
    A. Carvalho, R. W. Colman, and R. S. Lees, Platelet function in hyperlipoproteinemia, N. Engl. J. Med., 290:434 (1974).Google Scholar
  79. 79.
    E. Tremoli, P. Maderna, M. Sirtori, and C. R. Sirtori, Platelet aggregation and malondialdehyde formation in type IIA hypercholesterolemic patients, Haemostasis, 8: 47 (1979).Google Scholar
  80. 80.
    E. Tremoli, G. C. Folco, E. Agradi, and C. Galli, Platelet thromboxanes and serum cholesterol, Lancet, 1: 107 (1979).Google Scholar
  81. 81.
    A. Zmuda, A. Dembinska-Kiec, A. Chytocwski, and R. J. Gryglewski, Experimental atherosclerosis in rabbits-platelet aggregation, Thromboxane A2 generation and anti-aggregating potency of prostacyclin, Prostaglandins, 16: 1035 (1977).CrossRefGoogle Scholar
  82. 82.
    S. J. Shattil, R. Anaya-Galindo, J. Bennett, R. W. Colman, and R. A. Cooper, Platelet hypersensitivity induced by cholesterol incorporation, J. Clin. Invest., 55:636 (1975).Google Scholar
  83. 83.
    M. J. Stuart, J. M. Gerrard, and J. G. White, Effect of cholesterol on production of thromboxane B by platelets in vitro, N. Engl. J. Med., 302:6 (1980).Google Scholar
  84. 84.
    J. W. Burch, N. Stanford and P. W. Majerus, Inhibition of platelet prostaglandin synthetase by oral aspirin, J. Clin. Invest., 61:314 (1978).Google Scholar
  85. 85.
    M. Buchanan and J. Hizsch, Comparison of in vivo and in vitro effects of platelet function suppressing drugs, in “Proceedings of the 5th Congress of the Intern. Society of Thrombosis and Haemostasis”, Paris, abstract 182 (1979).Google Scholar
  86. 86.
    S. Moncada, P. Korbut, S. Bunting, and J. R. Vane, Prostacyclin is a circulating hormone, Nature, 273: 767 (1978).Google Scholar
  87. 87.
    S. Moncada and J. R. Vane, Prostacyclin in the cardiovascular system, in “Adv. in Prostaglandin and Thromboxane Research”, vol. 6, B. Samuelsson, P. W. Ramwell and R. Paoletti, eds., Raven Press, New York, N.Y. (1980).Google Scholar
  88. 88.
    N. L. Baenziger, M. J. Dillender, and P. W. Majerus, Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin, Biochem. Biophys. Res. Comm., 78:294 (1977).Google Scholar
  89. 89.
    J. C. Kelton, J. Hirsch, C. J. Carter, and M. R. Buchanan, Thrombogenic effect of high-dose aspirin in rabbits, J. Clin. Invest., 62:892 (1978).Google Scholar
  90. 90.
    C. Patrono, G. Ciabattoni, E. Pinca, F. Pugliese, G. Castrucci, A. De Salvo, M. A. Satta, and B. A. Peskar, Low dose Aspirin and inhibition of thromboxane B2 production in healthy subjects, Throm. Res., 17:317 (1980).Google Scholar
  91. 91.
    S. Villa, M. Livio, and G. de Gaetano, The inhibitory effect of aspirin on platelet and vascular prostaglandins in rats cannot be completely dissociated, Brit. J. Haematol. 42:425 (1979).Google Scholar
  92. 92.
    G. Masotti, G. Galanti, S. Poggesi, R. Abbate, and G. G. Neri Serneri, Differential inhibition of prostacyclin production and platelet aggregation by aspirin, Lancet, ii: 1213 (1979).Google Scholar
  93. 93.
    E. Tremoli, P. Maderna, M. Sirtori, S. Colli, G. Corvi, and C. R. Sirtori, Indobufen therapy in type Ila hypercholes-terolemic subjects: effects on platelet function and malondialdehyde production, Haemostasis,Google Scholar
  94. 94.
    P. Mehta and J. Mehta, Platelet function studies in coronary heart disease. VIII. Decreased platelet sensitivity to prostacyclin in patients with myocardial ischaemia, Thromb. Res., 18:273 (1980).Google Scholar
  95. 95.
    J. Merino, M. Livio, G. Rajtar, and G. de Gaetano, Salicylate reverses in vitro aspirin inhibition of rat platelet and vascular prostaglandin generation, Biochem. Pharmacol., 29:1093 (1980).Google Scholar
  96. 96.
    S. Riegelman, The kinetic disposition of aspirin in human, in “Aspirin, Platelets and Stroke”, Background for a Clinical Trial, W. S. Fields and W. K. Hass, eds., p. 105, Wanen H. Green, St. Louis (1971).Google Scholar
  97. 97.
    M. B. Zucker and J. Peterson, Effect of acetylsalicylic acid, other nonsteroidal antiinflammatory agents and dipyri-damoleon human blood platelets, J. Lab. Clin. Med., 76:66 (1970).Google Scholar
  98. 98.
    D. C. B. Mills and J. B. Smith, The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′,5′ Cyclic monophosphate in platelets, Biochem. J., 121:185 (1971).Google Scholar
  99. 99.
    S. Moncada and R. Korbut, Dipyridamole and other phosphodiesterase inhibits act as antithrombotic agents by potentiating endogenous prostacyclin, Lancet, i: 1286 (1978).Google Scholar
  100. 100.
    L. A. Harker and S. J. Slichter, Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves, N. Engl. J. Med., 283:1302 (1970).Google Scholar
  101. 101.
    L. A. Harker, R. Ross, S. J. Slichter, and C. R. Scott, Homocistine induced aterosclerosis. The rate of endothelial cell injury and its response on his genesis, J. Clin. Invest., 58:731 (1976).Google Scholar
  102. 102.
    B. J. R. Whittle, S. Moncada, F. Whiting, and J. R. Vane, Carbacyclin, a potent stable prostacyclin analogue for the inhibition of platelet aggregation, Prostaglandins, 19: 605 (1980).Google Scholar
  103. 103.
    L. D. Tobias and J. G. Hamilton, Inhibition of Arachidonate metabolism by selected compounds in vitro with particular emphasis on the thromboxane A2 synthase pathway, in “Adv. in Prostaglandin and Thromboxane Research”, vol. 6, B. Samuelsson, P. W. Ramwell and R. Paoletti, eds., Raven Press, New York, N.Y. (1980).Google Scholar
  104. 104.
    J. Vermylen, D. A. F. Chamone, and M. Verstraete, Stimulation of prostacyclin release from vessel wall by BAY g 6575, an antithrombotic compound, Lancet, ii: 518 (1979).Google Scholar
  105. 105.
    S. Ashida and Y. Abiko, Effect of ticlopidine and acetyl salicylic acid on generation of prostaglandin I2-like substance in rat arterial tissue, Thromb. Res., 13:901 (1978).Google Scholar
  106. 106.
    W. S. Fields, N. A. Lemak, R. F. Frankowski, and R. L. Hardy, Controlled trial of aspirin in cerebral ischemia, Stroke, 8: 301 (1977).Google Scholar
  107. 107.
    The Canadian Cooperative Study Group, A randomized trial of aspirin and sulfinpyrazone in threatened stroke, N. Engl. J. Med., 299:53 (1978).Google Scholar
  108. 108.
    Aspirin Myocardial Infarction Study Research Group, A randomized, controlled trial of aspirin in persons recovered from myocardial infarction, JAMA, 243: 661 (1980).Google Scholar
  109. 109.
    P. C. Elwood, A. L. Cochrane, M. L. Burr, P. M. Sweetman, G. Williams, S. J. Hughes, and R. Renton, A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction, Br. Med. J., 1:436 (1974).Google Scholar
  110. 110.
    The Coronary Drug Project Research Group, Aspirin in coronary heart disease, J. Chronic Dis., 29:625 (1976).Google Scholar
  111. 111.
    The Anturane Reinfarction Trial Research Group, Sulfinpyrazone in the prevention of cardiac death after myocardial infarction, N. Engl. J. Med., 296:289 (1978).Google Scholar
  112. 112.
    The Persantin-Aspirin Reinfarction Study Research Group, Persantin and aspirin in coronary heart disease, Circulation, 62: 449 (1980).Google Scholar
  113. 113.
    J. Stamler, Diet-related risk factors for human atherosclerosis: hyperlipidemia, hypertension, hyperglycemia — current status, Adv. Exp. Med. Biol., 60: 125 (1975).PubMedGoogle Scholar
  114. 114.
    R. W. Wissler and D. Vesselinovitch, The effects of feeding various dietary fats on the development and regression of hypercholesterolemia and atherosclerosis, Adv. Exp. Med. Biol., 60:65 (1975).Google Scholar
  115. 115.
    S. Renaud, C. Allard, and J. G. Latour, Influence of the type of dietary saturated fatty acid on lipemia, coagulation and the production of thrombosis in the rat, J. Nutr., 90:433 (1966).Google Scholar
  116. 116.
    G. Hornstra, Specific effects of types of dietary fat on arterial thrombosis, in “The role of fats in human nutrition”, A. J. Vergroesen ed., Academic Press, New York, N.Y., p. 303 (1975).Google Scholar
  117. 117.
    L. McGregor and S. Renaud, Effect of dietary linoleic acid deficiency on platelet aggregation and phospholipid fatty acids of rats, Thromb. Res., 12:921 (1978).Google Scholar
  118. 118.
    C. Galli, C. Spagnuolo, E. Bosisio, L. Tosi, G. C. Folco, and G. Galli, Dietary essential fatty acids brain polyunsaturated fatty acids and prostaglandins in the central nervous system, in “Adv. Prostaglandins and Thromboxane Research”, vol. IV, F. Coceani and P. M. Olley, Raven Press, New York, N.Y., p. 181 (1978).Google Scholar
  119. 119.
    E. Agradi, E. Tremoli, C. Colombo, and C. Galli, Influence of short term dietary supplementation of different lipids on aggregation and arachidonic acid metabolism in rabbit platelets, Prostaglandins, 16: 973 (1978).Google Scholar
  120. 120.
    J. Dyerberg, H. O. Bang, E. Stoffersen, S. Moncada, and J. R. Vane, Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis, Lancet, 2: 117 (1978).Google Scholar
  121. 121.
    P. Needleman, H. Sprecher, M. O. Whitaker, and A. Wyche, Mechanism underlying the inhibition of platelet aggregation by eicosapentaenoic acid and its metabolites, in “Adv. in Prostaglandin and Thromboxane Research”, vol. 6, B. Samuelsson, P. W. Ramwell and R. Paoletti, Raven Press, New York, N.Y., p. 61 (1980).Google Scholar
  122. 122.
    A. Raz, M. S. Minkes and P. Needleman, Endoperoxides and thromboxanes. Structural determinants for platelet aggregation and vasoconstriction, Biochim. Biophys. Acta, 488: 305 (1977).Google Scholar
  123. 123.
    M. O. Whitaker, P. Needleman, A. Wyche, F. A. Fitzpatrick, and H. Sprecher, PGD3 is the mediator of the antiaggregatory effects of the trienoic Endoperoxide PGH3 in “Adv. in Prostaglandin and Thromboxane Research”, vol. 6, B. Samuelsson, P. W. Ramwell and R. Paoletti, Raven Press, New York, N.Y., p. 301 (1980).Google Scholar
  124. 124.
    P. Needleman, M. O. Whitaker, A. Wyche, K. Watten, H. Sprecher, and A. Raz, Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: pharmacological basis for a therapeutic approach, Prostaglandins, 19: 165 (1980).PubMedCrossRefGoogle Scholar
  125. 125.
    S. Hammarstrom, Leukotriene C5: a slow reacting substance derived from EPA, J. Biol. Chem., 255:7093 (1980).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • E. Tremoli
    • 1
  • C. Galli
    • 1
  • R. Paoletti
    • 1
  1. 1.Institute of Pharmacology and PharmacognosyUniversity of MilanMilanItaly

Personalised recommendations